Vermillion Appoints Dr. Judith K. Wolf as Chief Medical Officer

       Vermillion Appoints Dr. Judith K. Wolf as Chief Medical Officer

PR Newswire

AUSTIN, Texas, June 17, 2014

AUSTIN, Texas, June 17, 2014 /PRNewswire/ --Vermillion, Inc. (NASDAQ: VRML),
a multivariate diagnostics company focused on gynecologic cancers and women's
health, has appointed Dr. Judith K. Wolf to the new position of chief medical
officer, effective September 15, 2014.

Dr. Wolf is a highly accomplished, widely published and active professional in
the field of gynecologic cancer. Over the last eight years, she has held
numerous academic and administrative positions at the University of Texas and
Banner MD Anderson Cancer Centers, and currently serves as the division chief
of Surgical Oncology and vice chair of the Department of Oncology Services at
the Banner MD Anderson Cancer Center in Arizona.

"Dr. Wolf is an ideal fit for our expanding team of professionals," said James
LaFrance, Vermillion's chairman, president and CEO. "She has pursued an
exemplary career as a surgeon, administrator and patient advocate in
gynecological health, and her clinical knowledge, professional organization
skills and leadership abilities will be a tremendous asset as we work toward
increasing awareness and adoption of OVA1."

Dr. Wolf has co-authored 94 peer-reviewed research articles and was the
principal investigator or co-investigator for 11 research grants related to
gynecologic cancers. She has served as the principal investigator,
co-principal investigator or collaborator on 84 protocols, and has presented
at more than 50 conferences, as well as at numerous scientific exhibitions and
seminars.

Dr. Wolf is also presently an adjunct professor of gynecologic oncology at the
University of Texas MD Anderson Cancer Center, and a clinical professor of
Division of Clinical Education at Arizona College of Osteopathic Medicine. She
is also chairman of the Medical and Scientific Advisory Board of the National
Ovarian Cancer Coalition, and a member of the American Association of Cancer
Research, Felix Rutledge Society, Society of Gynecologic Oncology and American
Society of Clinical Oncology. Additionally, she is a fellow at the American
College of Obstetrics and Gynecology.

Dr. Wolf received her medical degree at Northeastern Ohio Universities College
of Medicine and Masters in Biomedical Sciences at The University of Texas
Health Science Center in Houston. She completed her residency in obstetrics
and gynecology at University of Texas Health Science Center in San Antonio,
and fellowships in gynecologic surgery at University of Minnesota and MD
Anderson. She is certified by the American Board of Obstetrics and Gynecology
with a special qualification in gynecologic oncology.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in gynecologic
oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical
assessment of ovarian tumors for malignancy, using an innovative algorithmic
approach. As the first FDA-cleared, protein-based In Vitro Diagnostic
Multivariate Index Assay, OVA1 represents a new class of software-based
diagnostics. For additional information, including published clinical trials,
visit www.vermillion.com.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is
defined in the Private Litigation Reform Act of 1995, that involve significant
risks and uncertainties, including statements regarding the activities of
ASPiRA LABS, Inc., Vermillion's future revenue and Vermillion's expected cash
outlay. Words such as "may," "expects," "intends," "anticipates," "believes,"
"estimates," "plans," "seeks," "could," "should," "continue," "will,"
"potential," "projects" and similar expressions are intended to identify
forward-looking statements. The forward-looking statements contained in this
press release are based on Vermillion's expectations as of the date of this
press release. A variety of factors could cause actual results and experience
to differ materially from the anticipated results or other expectations
expressed in such forward-looking statements. Factors that could cause actual
results to materially differ from those projected in such forward-looking
statements include but are not limited to: (1) uncertainty as to Vermillion's
ability to protect and promote its proprietary technology; (2) Vermillion's
lack of a lengthy track record successfully developing and commercializing
diagnostic products; (3) uncertainty as to whether Vermillion will be able to
obtain any required regulatory approval of its future diagnostic products or
otherwise comply with applicable laws and regulations; (4) uncertainty of the
size of market for its existing diagnostic tests or future diagnostic
products, including the risk that its products will not be competitive with
products offered by other companies, or that users will not be entitled to
receive adequate reimbursement for its products from third-party payers such
as private insurance companies and government insurance plans; (5) uncertainty
that Vermillion has sufficient cash resources to fully commercialize its tests
and continue as a going concern; (6) uncertainty regarding Vermillion's
ability to generate sufficient demand for ASPiRA LABS' services to cover the
laboratory's operating costs; (7) uncertainty whether the trading in
Vermillion's stock will become significantly less liquid; and (8) other
factors that are described in Vermillion's Form 10-K for the year ended
December 31, 2013 and Vermillion's Form 10-Q for the quarter ended March 31,
2014 filed with the Securities and Exchange Commission (the "SEC"). Vermillion
expressly disclaims any obligation to update, amend or clarify any
forward-looking statements to reflect events, new information or circumstances
occurring after the date of this press release, except as required by law.

This release should be read in conjunction with the consolidated financial
statements and notes thereto included in our most recent reports on Form 10-K
and Form 10-Q. Copies are available through the SEC's Electronic Data
Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
VRML@liolios.com

SOURCE Vermillion, Inc.

Website: http://www.vermillion.com
 
Press spacebar to pause and continue. Press esc to stop.